Cleveland, OHIO5 Active Studies

Bladder Cancer Clinical Trials in Cleveland, OHIO

Find 5 actively recruiting bladder cancer clinical trials in Cleveland, OHIO. Connect with local research sites and explore new treatment options.

5
Active Trials
4
Sponsors
991
Enrolling

Recruiting Bladder Cancer Studies in Cleveland

RecruitingCleveland, OHIONCT04561362

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tu...

329 participants
BicycleTx Limited
View Study Details
RecruitingCleveland, OHIONCT05544552

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including lo...

310 participants
Tyra Biosciences, Inc
View Study Details
RecruitingCleveland, OHIONCT06305767

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

Researchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins in cells that line the ins...

230 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingCleveland, OHIONCT06483334

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the safety and preliminary efficacy of s...

98 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingCleveland, OHIONCT06263153

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

This phase II trial tests how well the combination of futibatinib and durvalumab given before cystectomy works in treating patients with muscle-invasive bladder cancer (MIBC) who are ineligible for ci...

24 participants
Yuanquan Yang
View Study Details

About Bladder Cancer Clinical Trials in Cleveland

Bladder cancer occurs in the tissues of the bladder and is one of the most common cancers. It has a high recurrence rate, requiring ongoing monitoring. Treatments include surgery, intravesical therapy, chemotherapy, and immunotherapy.

There are currently 5 bladder cancer clinical trials recruiting participants in Cleveland, OHIO. These studies are seeking a combined 991 participants. Research is being sponsored by BicycleTx Limited, Tyra Biosciences, Inc, Merck Sharp & Dohme LLC and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Bladder Cancer Clinical Trials in Cleveland — FAQ

Are there bladder cancer clinical trials in Cleveland?

Yes, there are 5 bladder cancer clinical trials currently recruiting in Cleveland, OHIO. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Cleveland?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Cleveland research site will contact you about next steps.

Are clinical trials in Cleveland free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Cleveland studies also compensate for your time and travel.

What bladder cancer treatments are being tested?

The 5 active trials in Cleveland are testing new therapies including novel drugs, biologics, and treatment approaches for bladder cancer.

Data updated March 2, 2026 from ClinicalTrials.gov